135 related articles for article (PubMed ID: 24962571)
1. Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.
Tsukahara T; Emori M; Murata K; Hirano T; Muroi N; Kyono M; Toji S; Watanabe K; Torigoe T; Kochin V; Asanuma H; Matsumiya H; Yamashita K; Himi T; Ichimiya S; Wada T; Yamashita T; Hasegawa T; Sato N
J Biol Chem; 2014 Aug; 289(32):22035-47. PubMed ID: 24962571
[TBL] [Abstract][Full Text] [Related]
2. HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor.
Tsukahara T; Kawaguchi S; Torigoe T; Takahashi A; Murase M; Kano M; Wada T; Kaya M; Nagoya S; Yamashita T; Sato N
J Transl Med; 2009 Jun; 7():44. PubMed ID: 19523231
[TBL] [Abstract][Full Text] [Related]
3. Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells.
Watanabe K; Tsukahara T; Toji S; Saitoh S; Hirohashi Y; Nakatsugawa M; Kubo T; Kanaseki T; Kameshima H; Terui T; Sato N; Torigoe T
Cancer Sci; 2019 Jan; 110(1):40-51. PubMed ID: 30375705
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma.
Tsukahara T; Kawaguchi S; Torigoe T; Kimura S; Murase M; Ichimiya S; Wada T; Kaya M; Nagoya S; Ishii T; Tatezaki S; Yamashita T; Sato N
Cancer Sci; 2008 Feb; 99(2):368-75. PubMed ID: 18271936
[TBL] [Abstract][Full Text] [Related]
5. Development of an artificial antibody specific for HLA/peptide complex derived from cancer stem-like cell/cancer-initiating cell antigen DNAJB8.
Tadano H; Tsukahara T; Mizushima E; Akamatsu A; Watanabe K; Nojima I; Kubo T; Kanaseki T; Hirohashi Y; Sato N; Torigoe T
Br J Cancer; 2020 Oct; 123(9):1387-1394. PubMed ID: 32753678
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel human leukocyte antigen-A*11:01-restricted cytotoxic T-lymphocyte epitopes derived from osteosarcoma antigen papillomavirus binding factor.
Li D; Toji S; Watanabe K; Torigoe T; Tsukahara T
Cancer Sci; 2019 Apr; 110(4):1156-1168. PubMed ID: 30767336
[TBL] [Abstract][Full Text] [Related]
7. Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor.
Tsukahara T; Nabeta Y; Kawaguchi S; Ikeda H; Sato Y; Shimozawa K; Ida K; Asanuma H; Hirohashi Y; Torigoe T; Hiraga H; Nagoya S; Wada T; Yamashita T; Sato N
Cancer Res; 2004 Aug; 64(15):5442-8. PubMed ID: 15289353
[TBL] [Abstract][Full Text] [Related]
8. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.
Inaguma Y; Akahori Y; Murayama Y; Shiraishi K; Tsuzuki-Iba S; Endoh A; Tsujikawa J; Demachi-Okamura A; Hiramatsu K; Saji H; Yamamoto Y; Yamamoto N; Nishimura Y; Takahashi T; Kuzushima K; Emi N; Akatsuka Y
Gene Ther; 2014 Jun; 21(6):575-84. PubMed ID: 24694533
[TBL] [Abstract][Full Text] [Related]
9. Development of T cell receptor-engineered T cells targeting the sarcoma-associated antigen papillomavirus binding factor.
Hamada S; Tsukahara T; Watanabe Y; Murata K; Mizue Y; Kubo T; Kanaseki T; Hirohashi Y; Emori M; Nakatsugawa M; Teramoto A; Yamashita T; Torigoe T
Cancer Sci; 2024 Jan; 115(1):24-35. PubMed ID: 37879364
[TBL] [Abstract][Full Text] [Related]
10. Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes.
Oved K; Lev A; Noy R; Segal D; Reiter Y
Cancer Immunol Immunother; 2005 Sep; 54(9):867-79. PubMed ID: 15906027
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.
Hee Lee J; Park MS; Hwang JE; Cho SH; Bae WK; Shim HJ; Kim DE; Chung IJ
Cell Mol Immunol; 2013 May; 10(3):275-82. PubMed ID: 23524651
[TBL] [Abstract][Full Text] [Related]
12. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
13. Assessing vaccine potency using TCRmimic antibodies.
Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
[TBL] [Abstract][Full Text] [Related]
14. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
[TBL] [Abstract][Full Text] [Related]
15. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
16. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
[TBL] [Abstract][Full Text] [Related]
17. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
19. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
20. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]